Document Detail


The M4 transmembrane segment contributes to agonist efficacy differences between alpha1 and alpha3 glycine receptors.
MedLine Citation:
PMID:  19626554     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To date there are few compounds known to pharmacologically discriminate between alpha1 and alpha3 subunit-containing glycine receptors (GlyRs). The present study stemmed from an observation that the glycinergic agonists, taurine and beta-alanine, act with much lower agonist efficacy at alpha3 GlyRs than at alpha1 GlyRs. We sought to understand the structural basis of this difference to provide insights relevant to the development of alpha3-specific modulators as leads for the development of new anti-inflammatory analgesics. Using chimeras of alpha1 and alpha3 subunits, we identified the structurally divergent M4 transmembrane segment and C-terminal tail as a specific determinant of the efficacy difference. Because mutation of individual non-conserved M4 residues had little influence on agonist efficacies, the reduced agonist efficacy at alpha3 GlyRs is most likely a distributed effect of all non-conserved M4 residues. Given the lack of contact between M4 and other transmembrane segments, the efficacy differences are probably mediated by differential interactions with the surrounding lipid environment. This may explain why GlyR agonist efficacies differ among expression systems where membrane lipid composition is not conserved. It may also explain why GlyR agonist efficacy increases at high expression densities, as this would increase the propensity of receptors to cluster thereby inducing M4 segments of neighboring receptors to interact. This strong influence of M4 primary structure on partial agonist efficacy suggests that the relatively poorly conserved alpha3 GlyR M4 segment may be a promising domain to target in the search for alpha3 GlyR-specific modulators.
Authors:
Xuebin Chen; Timothy I Webb; Joseph W Lynch
Related Documents :
18325484 - Role of glycine receptors and glycine release for the neuroprotective activity of bilob...
15275654 - Pacemaker activity in hydra is modulated by glycine receptor ligands.
7689044 - Strychnine-sensitive glycine receptors in cultured primary neurons from rat neocortex.
2903914 - Glycine potentiates strychnine-induced convulsions: role of nmda receptors.
6326924 - The effect of mianserin on alpha-2 adrenergic receptor function in depressed patients.
10463794 - The dopaminergic innervation of the avian telencephalon.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2009-07-20
Journal Detail:
Title:  Molecular membrane biology     Volume:  26     ISSN:  1464-5203     ISO Abbreviation:  Mol. Membr. Biol.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-09-16     Completed Date:  2009-12-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9430797     Medline TA:  Mol Membr Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  321-32     Citation Subset:  IM    
Affiliation:
Queensland Brain Institute and School of Biomedical Sciences, University of Queensland, Brisbane, QLD 4072, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Sequence
Animals
Humans
Molecular Sequence Data
Mutation
Oocytes / metabolism
Protein Structure, Tertiary
Protein Subunits
Rats
Receptors, Glycine / agonists*,  chemistry,  genetics,  metabolism
Sequence Alignment
Structure-Activity Relationship
Taurine / metabolism
Xenopus
beta-Alanine / metabolism
Chemical
Reg. No./Substance:
0/Protein Subunits; 0/Receptors, Glycine; 0/glycine receptor alpha1; 0/glycine receptor alpha3 subunit; 107-35-7/Taurine; 107-95-9/beta-Alanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative ef...
Next Document:  Efficient translational rehabilitation randomised controlled trial designs using disease progress mo...